FDA approves New Therapy Aimed at a New Target in Esophageal Cancer at the GE Junction
The Food and Drug Administration (FDA) has approved Zolbetuximab (Vyloy) as a first-line treatment for patients with advanced HER2* [...]
Study finds Regimen that doesn’t include Radiation is Better than current Standard
A German study finds a 30% reduction in the risk of death among Esophageal Adenocarcinoma patients who were treated [...]
FDA Advisory Panel votes to limit some EC patients’ access to immunotherapy
In 2021, Esophageal Cancer patients and advocates celebrated the Food and Drug Administration’s approval of immunotherapies for patients with [...]
Take Your Passion to End Esophageal Cancer to Capitol Hill
DEADLINE FAST APPROACHING! Join ECAN on Capitol Hill in June as we advocate to end Esophageal Cancer with our [...]
Funding Available for Esophageal Cancer Prevention & Treatment Research
Millions are available for research into the prevention, detection, diagnosis, treatment, and survival of Esophageal Cancer through the Department [...]
Powerful Tool to Catch Esophageal Cancer Before It Starts
A newly released study of the benefits of the EsoGuard® Esophageal DNA test says it is a powerful screening [...]
National Cancer Prevention Month
“Our best treatment for Esophageal Cancer is preventing Esophageal Cancer.” ~ Dr. John C. Lipham, M.D. Chair, ECAN Board [...]
New Discovery: Inherited Gene Mutation linked to Esophageal Adenocarcinoma
A breakthrough by researchers at Case Western Reserve has led to the discovery of an Inherited Gene Mutation linked to [...]
ECAN Launches New, Animated Guide for Patients at Risk for Esophageal Cancer
With animations that illustrate how to prevent, detect, treat, and cure Esophageal Cancer, ECAN, in partnership with the International Society [...]
Genetic Game-Changer?
A new study finds that 9% of all Esophageal Adenocarcinoma (EAC) patients have mutations in cancer-predisposing genes, potentially opening the [...]